Galecto's $285M Investment Boosts Blood Cancer Treatment

Galecto Incorporateds stock surged 360% after acquiring Damora Therapeutics, focusing on MPNs. The deal secured $285M, enabling Galecto to advance DMR-zero-zero-one, a potential top-tier treatment, and combine it with GB-three-two-two-six for acute myeloid leukemia. Galecto aims to begin human trials in 2026.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.